hg202
Gene therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 4, 2023 (NCT06031727)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor AANTISENSE INHIBITOR
VEGFA antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06623279 | Phase 1 | Apr 1, 2025 | HuidaGene Therapeutics Co., Ltd. |
| NCT06031727 | Early Phase 1 (Phase 1) | Sep 4, 2023 | Fudan University, HuidaGene Therapeutics Co., Ltd., Tianjin Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HuidaGene Therapeutics Co., Ltd. | For profit | 2 | 2 | 1 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1